Ferumoxytol (Feraheme®, AMAG Pharmaceuticals, Waltham) is an injectable iron micro particle-solution approved by the FDA for treatment of iron-deficiency anemia. This medication also has favorable properties as intravascular blood pool agent (off-label) for contrast-enhanced MRA (Fe-MRA). Fe-MRA is an alternative modality for the assessment of pulmonary embolism without the need for ionizing radiation or gadolinium in pregnant patients. The purpose of this study was to summarize our clinical experience with 70 Fe-MRA exams in 66 pregnant patients. We aimed to demonstrate the safety and efficacy of Fe-MRA and provide guidance in establishing a clinical service.